NewAmsterdam Pharma Company N.V.
NAMS
$36.67
-$3.79-9.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.15M | 2.98M | 12.77M | 29.11M | 2.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.15M | 2.98M | 12.77M | 29.11M | 2.28M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 19.15M | 2.98M | 12.77M | 29.11M | 2.28M |
| SG&A Expenses | 27.26M | 27.15M | 21.11M | 18.41M | 16.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.78M | 71.90M | 56.00M | 54.11M | 54.85M |
| Operating Income | -35.64M | -68.93M | -43.23M | -25.00M | -52.58M |
| Income Before Tax | -17.36M | -39.53M | -92.18M | -16.65M | -39.01M |
| Income Tax Expenses | -- | -- | 0.00 | -1.00K | -- |
| Earnings from Continuing Operations | -17.36M | -39.53M | -92.18M | -16.65M | -39.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.36M | -39.53M | -92.18M | -16.65M | -39.01M |
| EBIT | -35.64M | -68.93M | -43.23M | -25.00M | -52.58M |
| EBITDA | -35.59M | -68.87M | -43.18M | -24.98M | -52.56M |
| EPS Basic | -0.15 | -0.34 | -0.93 | -0.18 | -0.41 |
| Normalized Basic EPS | -0.09 | -0.23 | -0.54 | -0.10 | -0.28 |
| EPS Diluted | -0.15 | -0.34 | -0.93 | -0.18 | -0.41 |
| Normalized Diluted EPS | -0.09 | -0.23 | -0.54 | -0.10 | -0.28 |
| Average Basic Shares Outstanding | 118.56M | 116.12M | 99.43M | 94.75M | 94.71M |
| Average Diluted Shares Outstanding | 118.56M | 116.12M | 99.43M | 94.75M | 94.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |